Elanco Animal Health (NYSE:ELAN) Posts Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Elanco Animal Health (NYSE:ELAN) released its quarterly earnings results on Wednesday. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07, FiscalAI reports. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same quarter in the previous year, the business earned $0.26 earnings per share. The firm’s revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health updated its Q3 2026 guidance to 0.190-0.220 EPS and its FY 2026 guidance to 1.100-1.160 EPS.

Here are the key takeaways from Elanco Animal Health’s conference call:

• Elanco reported 8% organic constant-currency revenue growth in Q2, with U.S. pet health and U.S. farm animal each up 11%; adjusted EBITDA rose 21% and adjusted EPS increased 31% year over year.
• Strong demand for Zenrelia and Credelio Quattro drove innovation revenue to $340 million in the quarter, prompting the company to raise its 2026 innovation revenue target to approximately $1.25 billion.
• Elanco raised full-year guidance to 6%-7% organic constant-currency revenue growth, $1.01-$1.035 billion of adjusted EBITDA, and $1.10-$1.16 of adjusted EPS; it also lowered its expected year-end net leverage ratio to approximately three times.
• Zenrelia treated more than 2.5 million dogs, reached 47 countries, and achieved first-line use in more than 40% of users, while Quattro expanded to over half of U.S. veterinary clinics; Befrena demand is reportedly exceeding expectations, though supply is expected to remain constrained until early 2027.
• Elanco plans to increase operating expenses by investing in direct-to-consumer marketing and product launches, with Q3 expenses expected to rise about 11% in constant currency; management also cited ongoing inflation and a seasonally more second-half-weighted margin profile.

Elanco Animal Health Stock Up 2.3%

Shares of NYSE ELAN traded up $0.60 during mid-day trading on Wednesday, reaching $26.20. The company had a trading volume of 11,415,152 shares, compared to its average volume of 5,377,977. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. Elanco Animal Health has a twelve month low of $13.76 and a twelve month high of $27.98. The stock’s 50 day moving average is $24.68 and its 200-day moving average is $24.09. The stock has a market capitalization of $13.08 billion, a PE ratio of -52.39, a price-to-earnings-growth ratio of 1.68 and a beta of 1.67.

Analyst Upgrades and Downgrades

ELAN has been the subject of a number of research analyst reports. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. TD Cowen upped their price target on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Citigroup increased their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Finally, JPMorgan Chase & Co. raised their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $28.73.

Trending Headlines about Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q2 results exceeded expectations. Revenue increased 10% year over year to $1.368 billion, while adjusted EPS was $0.34 versus the $0.27 analyst consensus and $0.26 a year earlier. Adjusted EBITDA reached $288 million, with an adjusted margin of 21.2%. Elanco Animal Health Reports Second Quarter 2026 Results
• Positive Sentiment: Management raised its full-year outlook. Elanco now expects 2026 revenue of $5.09 billion to $5.14 billion, adjusted EBITDA of $1.01 billion to $1.035 billion, and adjusted EPS of $1.10 to $1.16—above the prior consensus EPS estimate of $1.07. The company also raised its innovation-revenue target to $1.25 billion and improved its year-end net-leverage target to approximately 3.0 times adjusted EBITDA. Elanco posts Q2 beat as Zenrelia hits blockbuster status
• Positive Sentiment: Zenrelia reached blockbuster status. Strong demand for the allergy treatment supported Elanco’s innovation portfolio and reinforced investor confidence that newer products can drive growth. Elanco Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Third-quarter guidance calls for adjusted EPS of $0.19 to $0.22 and revenue of approximately $1.2 billion. The EPS range begins at the consensus estimate, indicating expectations are largely maintained rather than materially raised for the near term.
• Negative Sentiment: Reported net income was $54 million, and the company continues to carry meaningful leverage, with net debt at 3.1 times adjusted EBITDA. These factors remain risks despite the improved profitability and deleveraging targets.

Insiders Place Their Bets

In other news, CEO Jeffrey N. Simmons bought 4,971 shares of the stock in a transaction on Friday, May 15th. The shares were purchased at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the purchase, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at $3,454,897.39. This trade represents a 2.98% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Rajeev A. Modi bought 4,911 shares of the company’s stock in a transaction on Friday, May 15th. The stock was purchased at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the transaction, the insider owned 160,812 shares in the company, valued at approximately $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 1.14% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Elanco Animal Health

A number of hedge funds have recently added to or reduced their stakes in ELAN. Moors & Cabot Inc. acquired a new stake in Elanco Animal Health in the third quarter valued at approximately $206,000. Kotler Kevin acquired a new position in shares of Elanco Animal Health during the 4th quarter worth $205,000. Kestra Advisory Services LLC acquired a new position in shares of Elanco Animal Health during the 4th quarter worth $168,000. Empowered Funds LLC raised its holdings in shares of Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after purchasing an additional 4,121 shares in the last quarter. Finally, Cresset Asset Management LLC raised its holdings in shares of Elanco Animal Health by 12.8% during the 2nd quarter. Cresset Asset Management LLC now owns 11,338 shares of the company’s stock valued at $162,000 after purchasing an additional 1,287 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.